Next Generation Dx Summit
Impact of PAMA Regulations on IVDs
Date: 19-August-2015
Time: 11 a.m. Eastern Daylight Time
Outside Speaker(s):
Julie Khani, Senior Vice President, American Clinical Laboratory Association
John F. Warren, Senior Director, McDermott+Consulting LLC
Donna Polizio, Senior Director, Managed Care & Reimbursement, Genomic Health
Paul W. Radensky, M.D., Partner, Health Products Regulation Group, McDermott Will & Emery LLP
Location:
Capital Hilton Hotel
1001 16th St. NW
Washington, D.C. 20036
Bruce Quinn, M.D., Ph.D., senior director in FaegreBDC's health and biosciences group, is speaking at the plenary session of the seventh annual Next Generation Dx Summit. His talk, "Impact of PAMA Regulations on IVDs," will explain how and why PAMA, legislation introduced in 2014, will affect the industry including clinical chemistry diagnostics, infectious disease diagnostics, point of care diagnostics, and sophisticated molecular tests.
How has the Medicare agency proposed to implement the law? How will advanced molecular tests and more common tests be impacted differentially? How will PAMA affect the adoption and acceptance of next generation sequencing? These questions and more will be answered in Dr. Quinn's session.
REGISTER FOR NEXT GENERATION DX SUMMIT.